Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Concizumab-mtci, is a humanized IgG4 monoclonal antibody produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells with an approximate molecular weight of 149 kDa.
Alhemo (concizumab-mtci) injection is a clear to slightly opalescent, and colorless to slightly yellow solution that may contain translucent to white particles. Alhemo is supplied as a single-patient-use prefilled pen for subcutaneous injection.
Each 1 mL of Alhemo single-patient-use prefilled pen (60 mg/1.5 mL) contains 40 mg active ingredient concizumab-mtci. Each 1 mL of Alhemo single-patient-use prefilled pen (150 mg/1.5 mL) contains 100 mg active ingredient concizumab-mtci. Each 1 mL of Alhemo single-patient-use prefilled pen (300 mg/3 mL) contains 100 mg active ingredient concizumab-mtci.
Each 1 mL of Alhemo single-patient-use prefilled pen contains the following excipients: arginine hydrochloride (5.27 mg), histidine (5.12 mg), phenol (3.5 mg), polysorbate 80 (0.25 mg), sodium chloride (1.46 mg), sucrose (51.3 mg), and water for injection.
Hydrochloric acid and sodium hydroxide may be added to adjust the pH to 6.0.
Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
For subcutaneous use only.
Alhemo should be administered once-daily. Avoid missed doses.
The calculated dose is rounded off to the nearest injectable dose as follows:
Additional measurements of concizumab-mtci plasma concentration should be taken at routine clinical follow-ups provided the patient has been on the same maintenance dose for 8 weeks of treatment to ensure steady-state plasma concentration. Maintenance of concizumab plasma concentration above 200 ng/mL is important to decrease the risk of bleeding episodes. If concizumab-mtci plasma concentration remains below 200 ng/mL at two consecutive measurements, the benefits of continued Alhemo treatment should be evaluated versus the potential risk of bleeding events, and alternative therapies if available should be considered.
As Alhemo is dosed by body weight (mg/kg), it is important to recalculate the dose when patients experience body weight changes.
Adherence to daily dosing of Alhemo is important to maintain protection againsst bleeding. This is especially important during the initial 4 weeks of treatment to ensure a correct maintenance dose is established. Patients who miss a dose during the initial 4-week period should inform their healthcare professional and resume once-daily dosing at the initial 0.2 mg/kg dose level.
Missed Doses Once The Maintenance Dose Has Been Established
The following dosing guidelines should apply ONLY when a patient has forgotten to or neglected to take their once-daily maintenance dose:
No dose adjustment of Alhemo is required in the case of breakthrough bleeds.
No dose adjustment of Alhemo is required in the case of minor surgeries.
As there is limited experience in the perioperative setting, it is generally recommended to pause Alhemo at least 4 days prior to major surgery. Alhemo therapy can be resumed 10–14 days after surgery on the same maintenance dose without a new loading dose, considering the overall clinical picture of the patient. If necessary, consult a physician experienced in surgery of patients with bleeding disorders.
The safety and efficacy of concomitant use of Alhemo in patients receiving ongoing Immune Tolerance Induction (ITI), a desensitization strategy for the eradication of inhibitors, have not been established, and no data are available. Careful assessment of the potential benefits and risks should be performed if continuation or initiation of Alhemo during ITI is considered.
Healthcare providers should discuss with patients receiving Alhemo and/or their caregivers the dose and schedule of bypassing agents or FVIII or FIX, if required, while receiving Alhemo prophylaxis.
Treatment with all bypassing agents (e.g., rFVIIa or aPCC) can be used for breakthrough bleeds, and the dose and duration will depend on the location and severity of the bleed.
For mild and moderate bleeds that require additional treatment with bypassing agents (e.g., rFVIIa or aPCC), the lowest-approved dose and the dose interval in the approved product labeling is recommended. For aPCC, a maximum dose of 100 units/kg body weight within 24 hours is recommended.
For severe bleeds, follow the dosing instructions provided in the approved labeling for the specific product based on clinical judgement.
Treatment is intended for use under the guidance of a healthcare provider. Treatment should be initiated in a non-bleeding state. Alhemo may be self-administered or administered by a caregiver after appropriate training and reading the Instructions for Use, if a healthcare provider determines that is appropriate.
Administer Alhemo by subcutaneous injection to the abdomen or thigh with rotation of injection site every day. Subcutaneous injections should not be given in areas where the skin is tender, bruised, red or hard, or areas where there are moles, scars, or stretch marks. Children and lean patients should be instructed to use injection techniques that minimize risk of intramuscular injection, e.g. injecting into a pinched fold of skin.
Always use a new needle for each injection.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Alhemo is a clear to slightly opalescent and colorless to slightly yellow solution that may contain translucent to white particles. Do not use if the solution is discolored.
Each Alhemo prefilled pen is for use by a single patient. An Alhemo pen must not be shared between patients, even if the needle is changed.
Alhemo is recommended to be used with NovoFine® or NovoFine® Plus needles with a gauge of 32 and a length of 4 mm. If needles longer than 4 mm are used, injection techniques that minimize the risk of intramuscular injection should be used.
Instructions for delivering the dosage are provided in the Instructions for Use leaflet enclosed with each Alhemo single-patient-use prefilled pen.
Alhemo injection is a clear to slightly opalescent and colorless to slightly yellow solution that may contain translucent to white particles, available in the following presentations:
Alhemo (concizumab-mtci) injection is a clear to slightly opalescent, colorless to slightly yellow liquid, that may contain translucent to white particles. Alhemo is available as one single-patient-use prefilled pen per carton in the following presentations (see Table 3):
Table 3 Alhemo Presentations
| Presentation | Label | NDC Number |
| 60 mg/1.5 mL (40 mg/mL) | Brown | 0169-2084-15 |
| 150 mg/1.5 mL (100 mg/mL) | Gold | 0169-2080-15 |
| 300 mg/3 mL (100 mg/mL) | White | 0169-2081-03 |
Before first use: Store in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze.
After first use: Store in a refrigerator at 36°F to 46°F (2°C to 8°C) or at room temperature below 86°F (30°C) for up to 28 days. Write the date of first use in the space provided on the carton. Discard the unused portion of the pen 28 days after first opening.
Store Alhemo with the cap on and in the original carton to protect from light. Alhemo should not be stored in direct sunlight, and the Alhemo pen should be kept away from direct heat. Do not freeze or store it close to a cooling element in a refrigerator (the part that cools the refrigerator). Do not use Alhemo if it has been frozen or stored at temperatures above 86°F (30°C).
Manufactured by: Novo Nordisk Inc. 800 Scudders Mill Road, Plainsboro, NJ 08536. Revised: Apr 2025
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.
The data in the WARNINGS AND PRECAUTIONS reflect exposure to Alhemo based on pooled data from clinical trials explorer3 (phase 1b), explorer4 (phase 2), explorer5 (phase 2), explorer7 (phase 3) and explorer8 (phase 3), in which a total of 320 male patients with hemophilia A with and without inhibitors and hemophilia B with and without inhibitors received at least one dose of Alhemo as routine prophylaxis. The patients were exposed for a total of 475 exposure years.
The data described below reflect exposure of 52 patients with HAwI and HBwI who were previously treated on-demand therapy and who were randomized in explorer7 to arm 1 to receive on- demand treatment with bypassing agents (n = 19) or arm 2 to receive Alhemo prophylaxis (n = 33) at the recommended dosing regimen [see Clinical Studies]. The median duration of treatment was 31.1 weeks (range 3.9, 72.9 weeks) in arm 1 (on- demand arm) and 40.1 weeks (range 3.1, 56.3 weeks) in arm 2 (Alhemo prophylaxis).
Serious adverse reactions were reported in 6.1% of patients who received Alhemo. These serious adverse reactions were renal infarct and hypersensitivity reaction. Permanent discontinuation of Alhemo due to an adverse reaction occurred in 1 patient due to a renal infarct. Dosage interruptions of Alhemo due to an adverse reaction occurred in 1 patient (3%) and was a hypersensitivity reaction. The most common adverse reactions (≥5%) were injection site reactions and urticaria (see Table 1).
Table 1. Adverse Reactions Reported in ≥5% HAwI and HBwI Patients Randomized to Alhemo in Explorer7
| Adverse Reaction | Alhemo Prophylaxis N=33 (%) |
On-demand Treatment N=19 (%) |
| Injection site reactions | 18% | 0% |
| Urticaria | 6% | 0% |
| Injection site reactions included: Injection site bruising, Injection site erythema, Injection site hematoma, Injection site hemorrhage, Injection site reaction and Injection site urticaria. Urticaria included: Urticaria and Injection site urticaria |
||
Take appropriate precautions when treating break-through bleeding events in hemophilia patients receiving Alhemo prophylaxis and a bypassing agent [see DOSAGE AND ADMINISTRATION]. For mild and moderate bleeds that require additional treatment with bypassing agents (e.g., rFVIIa or aPCC), the lowest-approved dose in the approved product labeling is recommended. For aPCC, a maximum dose of 100 units/kg body weight within 24 hours is recommended. For severe bleeds, follow the dosing instructions provided in the approved labeling for the specific product based on clinical judgement.
Additive and sometimes synergistic increase in thrombin peak as quantified in the thrombin generation assay has been observed in plasma from hemophilia patients who were on prophylactic treatment with concizumab-mtci with concomitant presence of rFVIII, rFIX or bypassing agents including rFVIIa and aPCC [see CLINICAL PHARMACOLOGY].
Included as part of the "PRECAUTIONS" Section
Venous and arterial thromboembolic events were reported in 1.3% of patients (4/320) in Alhemo clinical trials. These cases occurred in patients with multiple risk factors for thromboembolism, including the use of high doses or prolonged treatment with factor product or bypassing agent (2 of 4 events).
Risk factors for thromboembolism may include the use of high and/or frequent doses of breakthrough bleed treatments (factor products or bypassing agents) or conditions in which tissue factor is overexpressed (e.g., atherosclerotic disease, crush injury, cancer, disseminated intravascular coagulation, thrombotic microangiopathy, or septicemia).
Inform Alhemo treated patients of signs and symptoms of thromboembolic events. Monitor patients for thromboembolic events. In case of suspicion of thromboembolic events, discontinue Alhemo and initiate further investigations and management strategies.
Alhemo is contraindicated in patients with a history of known serious hypersensitivity to Alhemo or its components or the inactive ingredients. Hypersensitivity reactions including erythema, rash, pruritus, and abdominal pain have occurred in Alhemo treated patients. One patient (less than 1% of patients treated in the clinical studies) experienced anaphylaxis which resolved after treatment with antihistamines and corticosteroids. Instruct patients of the signs of acute hypersensitivity reactions. Instruct patients to contact their healthcare provider for mild reactions and to seek urgent medical attention for moderate to severe reactions. Discontinue Alhemo if severe hypersensitivity symptoms occur, and initiate medical management.
Increased levels of fibrin D-dimer and increased levels of prothrombin fragment 1.2 were seen in 29 (9.1%) and 18 (5.6%) of patients, respectively. The plasma concentration of concizumab-mtci is positively correlated with fibrin D-dimer and prothrombin fragments 1.2 indicating a hemostatic effect of concizumab-mtci. For patients taking Alhemo, these coagulation biomarkers may not be reliable predictive markers for clinical decision-making with suspicion of thrombosis such as deep vein thrombosis (DVT) and pulmonary embolism (PE).
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Advise patients on the importance of adherence to daily dosing and to speak with their healthcare provider before discontinuing treatment with Alhemo as patients who are not adhering to daily dosing or stop treatment with Alhemo may no longer be protected against bleeding.
Advise patients to follow the recommendations regarding proper sharps disposal provided in the FDA-approved Instructions for Use.
No long-term animal studies have been conducted to evaluate the carcinogenic potential of concizumab-mtci nor have studies been performed to determine the effects of concizumab-mtci on genotoxicity.
In a 26-week toxicity study in sexually mature male and female cynomolgus monkeys with subcutaneous doses up to 9 mg/kg/day (corresponding to 3400-fold the human exposure, based on AUC0 to 24h), concizumab-mtci did not affect fertility (testicular size, sperm functionality or menstrual cycle duration) and did not cause any changes in the male or female reproductive organs.
Based on its mechanism of action, Alhemo may cause fetal harm when administered to a pregnant woman [see CLINICAL PHARMACOLOGY]. There are no available data on Alhemo use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with Alhemo. Although there are no data on concizumab-mtci, monoclonal antibodies can be actively transported across the placenta, and concizumab-mtci may cause fetal harm. It is unknown whether Alhemo can affect reproductive capacity. Alhemo should only be used during pregnancy if the potential benefit for the mother outweighs the potential risk to the fetus.
The estimated background risk of birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
There is no information regarding the presence of Alhemo in either human or animal milk, the effect on the breastfed child, or the effects on milk production.
Human IgGs are known to be excreted in breast milk during the first few days after birth, decreasing to low concentrations soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short period. Afterwards, Alhemo could be used during breast-feeding if clinically needed.
Pregnancy testing is recommended for females of reproductive potential.
Women of childbearing potential should use a highly effective form of contraception during treatment with Alhemo and for 7 weeks after ending treatment. The benefits and thromboembolic risks of the type of contraceptives used should be evaluated by the treating physician.
The safety and effectiveness of Alhemo for hemophilia A and B with inhibitors have been established in pediatric patients aged 12 years and older. Use of Alhemo for this indication is supported by evidence from adequate and well-controlled studies in adult and pediatric patients aged 12 years and older [see ADVERSE REACTIONS and Clinical Studies]. The safety and effectiveness of Alhemo for hemophilia A and B with inhibitors have not been established in pediatric patients younger than 12 years of age.
Clinical studies of Alhemo did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.
The apparent clearance and volume of distribution of concizumab-mtci decreased with increasing body weight [see CLINICAL PHARMACOLOGY]. However, patients should receive the approved recommended Alhemo dosage titration and concizumab-mtci plasma concentration monitoring regardless of body weight [see DOSAGE AND ADMINISTRATION].
No information provided
Alhemo is contraindicated in patients with a history of known serious hypersensitivity to Alhemo or its components or the inactive ingredients [see WARNINGS AND PRECAUTIONS and DESCRIPTION].
Concizumab-mtci is a monoclonal antibody antagonist of endogenous Tissue Factor Pathway Inhibitor (TFPI). Through the inhibition of TFPI, concizumab-mtci acts to enhance FXa production during the initiation phase of coagulation which leads to improved thrombin generation and clot formation with the goal of achieving hemostasis in patients with Hemophilia A or B with inhibitors. The effect of concizumab-mtci is not influenced by the presence of inhibitory antibodies to FVIII or FIX. There is no structural relationship or sequence homology between concizumab-mtci and FVIII or FIX and, as such, treatment with concizumab-mtci does not induce or enhance the development of direct inhibitors to FVIII or FIX.
Increasing concizumab-mtci dose levels resulted in decreased levels of free TFPI (plasma TFPI not bound to concizumab-mtci) and increased duration of free TFPI suppression. Free TFPI plasma levels pre-dose decreased from a geometric mean (CV%) of 88.3 (20%) ng/mL at baseline to 10.7 (105%) ng/mL at week 24 in patients on Alhemo prophylaxis, while the geometric mean (CV%) was 76.0 (18%) ng/mL at week 24 for patients on no Alhemo prophylaxis. Mean thrombin peak within the range of normal plasma reflected that concizumab-mtci re–established thrombin generation capacity.
Additive and sometimes synergistic increase in thrombin peak as quantified in the thrombin generation assay has been observed in plasma from hemophilia patients who were on prophylactic treatment with concizumab-mtci with concomitant presence of rFVIII, rFIX or bypassing agents including rFVIIa and aPCC. Depending on concentrations of concizumab-mtci and hemostatic agents, the impact on thrombin peak ranged from being additive with all hemostatic agents to an extra 40% effect with rFVIIa, an extra 33% effect with aPCC, an extra 22% with rFVIII and less than 13% with rFIX.
Peak and trough geometric mean plasma concizumab-mtci concentrations at steady state are shown in Table 2. Following a single Alhemo loading dose of 1 mg/kg, the steady state concentrations were reached around Day 4 and remained within a stable exposure range with daily maintenance doses. Concizumab-mtci AUC and Cmax increased with increasing dose in a greater than doseproportional manner following subcutaneous administration.
Table 2 Steady state concizumab-mtci concentrations during 24-hour dosing interval at week 24
| Parameters | HAwI and HBwI All maintenance doses N=99a |
| Cmax,ss (ng/mL), geometric mean (CV%) | 1167.1 (128%) |
| Ctrough,ss (ng/mL), geometric mean (CV%) | 665.4 (221%) |
| Cmax / Ctrough ratio, mean (SD) | 2.2 (5.2) |
| Abbreviations: Cmax,ss, maximum plasma concentration at steady state; Ctrough,ss, trough plasma concentration at steady state; HAwI, hemophilia a with inhibitors; HBwI, hemophilia B with inhibitors. aOn concizumab-mtci dosing regimen |
|
Concizumab-mtci time to maximum plasma concentration ranged from 8 hours to 99 hours (4.1 days) following a single Alhemo subcutaneous dose of 0.05 to 3 mg/kg in healthy and hemophilia subjects.
Concizumab-mtci volume of distribution for a typical 70 kg patient is about 3 L.
Concizumab-mtci is cleared via linear and non-linear mechanisms. Concizumab-mtci exhibited non-linear pharmacokinetics due to target-mediated drug disposition (TMDD) which occurs when it forms concizumab-mtci/TFPI complex. Once the target becomes saturated, linear pathway (i.e., catabolism) dominates.
Based on population pharmacokinetic analysis, 90% of concizumab-mtci is expected to be eliminated by the end of approximately 4 days after the last dose (time for 50% of drug to be eliminated is approximately 1 day).
Metabolism
Concizumab-mtci is expected to be metabolized into small peptides by catabolic pathways.
No clinically significant differences in the pharmacokinetics of concizumab-mtci were observed based on age (12 year to 79 years), race (White 62.9%, Asian 25.0%, Black 6.0%), hemophilia type (A vs B). No dedicated studies have been conducted to evaluate the impact of renal or hepatic impairment. As concizumab-mtci is a monoclonal antibody, there is no expectation for concizumab-mtci exposures to be different in patients with renal or hepatic impairment.
The apparent clearance and volume of distribution of concizumab-mtci increased with increasing body weight (27 kg to 130.7 kg) [see Use In Specific Populations].
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and the specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies (ADA) in the studies described below with the incidence of ADA in other studies, including those of concizumab-mtci or of other concizumab products.
During the treatment period in 4 trials with a duration of 11 weeks, ≥76 weeks, ≥76 weeks, and ≥32 weeks, 47 out of the 185 treated patients (25.4%) developed anti-concizumab-mtci antibodies. Among the 47 patients who tested positive for ADA, 12 patients (25.5%) developed neutralizing antibodies (NAbs) against concizumab-mtci. In 1 patient who developed NAb against concizumabmtci, free TFPI levels were restored to baseline indicative of effectiveness likely being compromised. In the remaining 46 patients, there was no identified clinically significant effect of the antibodies on pharmacokinetics, pharmacodynamics, safety, or effectiveness of concizumab-mtci.
No clinically significant interference with standard prothrombin and activated partial thromboplastin time assays or FVIII or FIX activity measurement using clot and chromogenic assays was observed with concizumab-mtci. Further, no clinically relevant interference with assays for inhibitory antibodies to FVIII or FIX (Bethesda assay) was observed with concizumab-mtci.
Pharmacology mediated formation of thrombi manifested in cynomolgus monkeys dosed subcutaneously during toxicology studies of 13-weeks (≥ 10 mg/kg/day), 26-weeks (≥ 3 mg/kg/day) and 52-weeks (≥ 1 mg/kg/day) in duration corresponding to ≥ 3732-fold, ≥ 955- fold and ≥ 308-fold, respectively, the human clinical exposure based on AUC0 to 24h in patients with Hemophilia A or B at the MRHD.
In a 28-day drug-drug interaction toxicity study in cynomolgus monkey with daily dosing of 1 mg/kg concizumab-mtci to achieve steady state, three consecutive intravenous doses of up to 1 mg/kg rFVIIa were administered with 2-hour intervals to the concizumab-mtci dosed animals. No adverse findings were observed at a concizumab-mtci exposure corresponding to 205-fold the human exposure, based on AUC0 to 24h.
The efficacy of Alhemo in patients with hemophilia A and B with inhibitors was evaluated in the explorer7 trial (NCT04083781), a multi-national, multi-center, open-label, phase 3 trial that investigated the safety and efficacy of Alhemo for routine prophylaxis in 91 adults (58 HAwI and 33 HBwI) and 42 adolescents (22 HAwI and 20 HBwI) male patients with hemophilia A or B with inhibitors who have been prescribed, or are in need of, treatment with bypassing agents. Eptacog alfa was the rFVIIa used in explorer7. Patients were excluded if they had a history, current signs or symptoms, or at high risk of thromboembolic events, ongoing or planned immune tolerance induction treatment, in addition to patients with planned major surgery.
Among the 133 patients treated with Alhemo in the trial the mean age was 29 years (range: 12 to 79); 42 patients were 12 to <18 years of age, 89 patients were 18 to 64 years of age, and 2 patients were ≥65 years of age, and all were male. Seventy-eight (78) patients were White, 37 patients were Asian, 9 patients were Black or African American, 6 patients had race information unreported, and 3 patients were American Indian or Alaska Native; 6 patients identified as Hispanic or Latino, 122 patients identified as not Hispanic or Latino and 5 patients had ethnicity information unreported.
The trial was comprised of 4 arms, two randomized arms and two non-randomized arms:
Treatment with Alhemo included a loading dose of 1 mg/kg on the first day and a once-daily dose of 0.20 mg/kg starting on the second day. The dose was individualized to 0.25 mg/kg or 0.15 mg/kg if Alhemo plasma concentration measured once after 4 weeks of treatment was <200 ng/mL or >4000 ng/mL, respectively. Measurement of concizumab-mtci plasma concentration after 4 weeks was used to optimize the daily maintenance dose. In the trial, a total of 108 patients received their individualized dose, 1 patient on 0.15 mg/kg, 79 patients on 0.20 mg/kg and 28 patients on 0.25 mg/kg.
Efficacy was evaluated in hemophilia A and B patients with inhibitors when all patients in arms 1 and 2 had completed at least 24 or at least 32 weeks, respectively), by comparing the number of treated bleeding episodes between Alhemo prophylaxis (arm 2) and no prophylaxis (arm 1). Using a negative binomial model, a ratio of the annualized bleeding rates (ABR) was estimated to 0.14 (p<0.001), corresponding to a reduction in ABR of 86% for subjects on Alhemo prophylaxis compared to no prophylaxis. The estimated mean ABR was 1.7 [95%CI: 1.01; 2.87] for patients on Alhemo prophylaxis (arm 2) and 11.8 [95%CI: 7.03; 19.86] for patients on no prophylaxis (arm 1).
Alhemo®
(al-HEE-mo)
(concizumab-mtci) injection, for subcutaneous use
What is the most important information I should know about Alhemo?
See “How should I use Alhemo?” for more information on how to use Alhemo.
What is Alhemo?
Alhemo is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.
It is not known if Alhemo is safe and effective in people using Alhemo while receiving ongoing Immune Tolerance Induction (ITI).
It is not known if Alhemo is safe and effective for hemophilia A and B with and without inhibitors in children younger than 12 years of age.
Do not use Alhemo if you are allergic to concizumab-mtci or any of the ingredients in Alhemo. See the end of this Medication Guide for a complete list of ingredients in Alhemo.
Before using Alhemo, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I use Alhemo?
Read the Instructions for Use that comes with Alhemo for information about how to prepare and inject a dose of Alhemo, and how to properly throw away (dispose of) used Alhemo pens and needles.
What are the possible side effects of Alhemo?
Alhemo may cause serious side effects, including:
The most common side effects of Alhemo include:
These are not all the possible side effects of Alhemo.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Alhemo?
Keep Alhemo and all medicine out of the reach of children.
General information about the safe and effective use of Alhemo.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Alhemo for a condition for which it was not prescribed. Do not give Alhemo to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Alhemo that is written for health professionals.
What are the ingredients in Alhemo?
Active ingredient: concizumab-mtci
Inactive ingredients: arginine hydrochloride, histidine, phenol, polysorbate 80, sodium chloride, sucrose, and water for injection. Hydrochloric acid and sodium hydroxide may be added for pH adjustment.
INSTRUCTIONS FOR USE
Alhemo®
(al-HEE-mo)
(concizumab-mtci)
injection, for subcutaneous use
60 mg/1.5 mL (40 mg/mL) single-patient-use prefilled pen
 |
This Instructions for Use contains information on how to inject Alhemo. Read and understand these instructions before you use the Alhemo pen. Make sure you have received training from your healthcare provider before you inject with this pen for the first time.
Gather the following supplies:
Supplies you will need that are not included in the carton:
Where on my body should I inject my dose?
 |
1. Check your Alhemo pen
 |
2. Attach a new needle
 |
Note: Always use a new needle for each injection.
3. Prime before each dose. Dial to ‘0.4’ and test the flow before each dose
 |
 |
4. Select your dose
 |
5a. Prepare the injection site
Read Steps 5a and 5b before you start injecting. This is to make sure you get your full dose.
 |
5b. Inject Alhemo
 |
The pen clicks during the injection and you might also hear or feel a click when the dose counter returns to “0”.
6. Remove the needle
 |
Do you need a larger dose than you can dial?
Repeat Steps 1 to 6 until you have received your full dose. When you have received your full dose go to Step 7.
Note: Only split your dose if you have been trained or told by your healthcare provider on how to do this.
7. Recap the pen
 |
Important information you need to know before injecting Alhemo
Important information about needles
Troubleshooting if no stream appears when testing the flow (Step 3)
How much Alhemo is left in your pen?
The pen scale shows about how much Alhemo is left in your pen. In the example below, 24 milligrams (mg) is remaining in the pen.
 |
If you want to see more accurately how much Alhemo is left in your pen, turn the dose selector until it stops. The dose pointer will line up with the number of mg left in the pen.
If the dose counter shows 32 mg, at least 32 mg is left in the pen. If the dose counter shows less than 32 mg, the number shown in the dose counter is the number of mg left in your pen. In the example below, the dose counter shows 13.6 mg, so there is 13.6 mg of Alhemo left in the pen.
 |
Storing Alhemo
Keep Alhemo and all medicine out of the reach of children.
Throwing away (disposing of) Alhemo pens, needles and needle caps
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
INSTRUCTIONS FOR USE
Alhemo®
(al-HEE-mo)
(concizumab-mtci)
injection, for subcutaneous use
150 mg/1.5 mL (100 mg/mL) single-patient-use prefilled pen
 |
This Instructions for Use contains information on how to inject Alhemo. Read and understand these instructions before you use the Alhemo pen. Make sure you have received training from your healthcare provider before you inject with this pen for the first time.
Gather the following supplies:
Supplies you will need that are not included in the carton:
Where on my body should I inject my dose?
 |
1. Check your Alhemo pen
2. Attach a new needle
Note: Always use a new needle for each injection.
 |
 |
3. Prime before each dose. Dial to ‘1’ and test the flow before each dose
 |
 |
4. Select your dose
 |
5a. Prepare injection site
Read through Steps 5a and 5b before you start injecting. This is to make sure you get your full dose.
 |
5b. Inject Alhemo
 |
The pen clicks during the injection and you might also hear or feel a click when the dose counter returns to “0”.
6. Remove the needle
 |
Do you need a larger dose than you can dial?
Repeat Steps 1 to 6 until you have received your full dose. When you have received your full dose go to Step 7.
Note: Only split your dose if you have been trained or told by your healthcare provider on how to do this.
7. Recap the pen
 |
Important information you need to know before injecting Alhemo
Important information about needles
Troubleshooting if no stream appears when testing the flow (Step 3)
How much Alhemo is left in your pen?
The pen scale shows about how much Alhemo is left in your pen. In the example below, 60 milligrams (mg) is remaining in the pen.
 |
If you want to see more accurately how much Alhemo is left in your pen, turn the dose selector until it stops.
The dose pointer will line up with the number of mg left in the pen.
If the dose counter shows 80 mg, at least 80 mg is left in the pen. If the dose counter shows less than 80 mg, the number shown in the dose counter is the number of mg left in your pen. In the example below, the dose counter shows 34 mg, so there is 34 mg of Alhemo left in the pen.
 |
Storing Alhemo
Keep Alhemo and all medicine out of the reach of children.
Throwing away (disposing of) Alhemo pens, needles, needle caps
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
INSTRUCTIONS FOR USE
Alhemo®
(al-HEE-mo)
(concizumab-mtci)
injection, for subcutaneous use
300 mg/3 mL (100 mg/mL) single-patient-use prefilled pen
 |
This Instructions for Use contains information on how to inject Alhemo. Read and understand these instructions before you use the Alhemo pen. Make sure you have received training from your healthcare provider before you inject with this pen for the first time.
Gather the following supplies:
Supplies you will need that are not included in the carton:
Where on my body should I inject my dose?
 |
1. Check your Alhemo pen
2. Attach a new needle
Note: Always use a new needle for each injection.
 |
 |
3. Prime before each dose. Dial to ‘1’ and test the flow before each dose
 |
 |
4. Select your dose
 |
5a. Prepare the injection site
Read through Steps 5a and 5b before you start injecting. This is to make sure you get your full dose.
 |
5b. Inject Alhemo
 |
The pen clicks during the injection and you might also hear or feel a click when the dose counter returns to “0”.
6. Remove the needle
 |
Do you need a larger dose than you can dial?
Repeat Steps 1 to 6 until you have received your full dose. When you have received your full dose go to Step 7.
Note: Only split your dose if you have been trained or told by your healthcare provider on how to do this.
7. Recap the pen
 |
Important information you need to know before injecting Alhemo
Important information about needles
Troubleshooting if no stream appears when testing the flow (Step 3)
How much Alhemo is left in your pen?
The pen scale shows about how much Alhemo is left in your pen. In the example below, 200 milligrams (mg) is remaining in the pen.
 |
If you want to see more accurately how much Alhemo is left in your pen, turn the dose selector until it stops. The dose pointer will line up with the number of mg left in the pen.
If the dose counter shows 80 mg, at least 80 mg is left in the pen. If the dose counter shows less than 80 mg, the number shown in the dose counter is the number of mg left in the pen. In the example below, the dose counter shows 34 mg, so there is 34 mg of Alhemo left in the pen.
 |
Storing Alhemo
Keep Alhemo and all medicine out of the reach of children.
Throwing away (disposing of) Alhemo pens, needles, needle caps
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
